La Jolla Pharmaceutical (LJPC) announced Monday morning that its Phase 3 study of LJPC-501 in patients with catecholamine resistant hypotension was highly statistically significant in terms of its primary endpoint. Only 23% of the 158 placebo-treated patients had a blood pressure response compared to 70% of the 163 LJPC-501-treated patients.
from RTT - Hot Stocks http://ift.tt/2mCKCJu
via IFTTT
No comments:
Post a Comment